New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 2mg - solution for injection - 2 mg - active: vincristine sulfate 2mg excipient: lactose monohydrate water for injection sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 5mg - solution for injection - 5 mg - active: vincristine sulfate 5mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: sulfuric acid; water for injections; mannitol; sodium hydroxide - vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of: 1. leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukemia and blastic crisis of chronic myelogenous leukaemia. 2. malignant lymphomas, including hodgkin's disease and non-hodgkin's lymphomas. 3. multiple myeloma. 4. solid tumors, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas. 5. paediatirc solid tumors, including ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, wilm's tumour, retinoblastoma and medulloblastoma. 6. idiopathic thrombocytytopenic pupura.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - vincristine sulfate is indicated alone or in combination with other antitumour therapies for the treatment of: - acute leukaemia - malignant leukaemias, including hodgkin's disease, non-hodgkin's lymphomas (lymphocytic, mixed cells, histiocytic, undifferentiated, nodular and diffuse types) - rhabdomyosarcoma - neuroblastoma - wilms? tumour - osteogenic sarcoma - mycosis fungoides - ewing?s sarcoma - breast cancer - malignant melanoma - small cell lung cancer - gynecological tumours of childhood, true idiopathic thrombocytopenic purpura, refractory to splenectomy and to short-term treatment with adrenocortical steroids.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - vincristine sulfate is indicated alone or in combination with other antitumor therapies for the treatment of: leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic mylogenous leukaemia, malignant lymphomas, including hodgkin?s disease and non-hodgkin?s lymphomas lung cancer (small cell bronchogenic carcinoma) wilms? tumor neuroblastoma ewing?s sarcomas true idiopathic thrombocytopenic purpura rhabdomyosarcoma

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections; nitrogen - vincristine sulfate is indicated alone or in combination with other antitumor therapies for the treatment of: -leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic mylogenous leukaemia -malignant lymphomas, including hodgkin?s disease and non-hodgkin?s lymphomas -lung cancer (small cell bronchogenic carcinoma) -wilms? tumor -neuroblastoma -ewing?s sarcomas -true idiopathic thrombocytopenic purpura -rhabdomyosarcoma

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hospira malaysia sdn bhd - vincristine sulphate -

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk ltd - vincristine sulfate - solution for injection - 5 mg/5ml

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - this medicine is indicated in certain diseases of the blood and in certain tumours.